We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

A new rapid point-of-care PCR test detects Mycobacterium tuberculosis from tongue swab or sputum. More...
13 Nov 2026
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Several AMP 2026 studies highlight AI’s potential in molecular pathology while addressing reliability, validation, and expert oversight. More...
13 Nov 2026
Image: The recommendations advise PSA testing every two years for average-risk men aged 50–69, with screening beginning at 45 for Black men and those with a strong family history.( Image Credit: iStock)

Updated PSA Testing Guidelines Support Early Prostate Cancer Detection

The American Cancer Society has issued updated prostate cancer screening guidelines emphasizing regular PSA testing. More...
13 Nov 2026
Image: Together, the AMP 2026 studies highlight the expanding role of molecular diagnostics in genetic disease detection, pediatric cancer classification, and infectious disease surveillance. (Image Credit: Adobe Stock)

AMP 2026 Highlights Advances in Molecular Testing for Pediatric Diseases

The AMP 2026 Annual Meeting & Expo features six studies on genetic disease detection, pediatric oncology, and infectious disease surveillance. More...
13 Nov 2026
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera and Incyte are collaborating on a Phase II study of MRD-guided treatment in colorectal cancer. More...
13 Nov 2026
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

An AI training strategy that weights topological errors improves cell counting and localization in digital pathology images. More...
13 Nov 2026
Image Credit: Adobe Stock

Genomic Studies Investigate Treatment Response and Inherited Risk in Sarcoma

New data show multimodal DNA/RNA and digital pathology profiling enables biomarker discovery and subtyping in rare sarcomas. More...
13 Nov 2026
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Gold Member
Aspiration System
VACUSAFE